Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 10 · below the Ichimoku cloud · RSI 22 (oversold) · MACD below its signal
None of the 29 investors followed here reported a position in SABS in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a SABS trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 28, 2025 | Sessa Capital Master, L.P.Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security at price 1.75 per share. | 1.74M | $3.04M |
| Sep 28, 2025 | Moin Andrew D.Director | Conversion of Exercise of derivative security at price 1.75 per share. | 1.74M | $3.04M |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 17.4 | -6.6 | -6.6 | -2.3 | -3.7 | 8.3 | -8.5 | 3.9 | -14.6 | -21.5 | −33.4% | ||
| 2025 | -42.3 | -21.9 | -20.5 | 25.0 | 13.5 | -9.1 | 7.1 | 10.6 | -3.4 | 61.7 | 21.5 | -5.3 | −1.4% |
| 2024 | -12.8 | -25.7 | 1.8 | -5.5 | -38.5 | 17.4 | -10.5 | 5.9 | -8.2 | 20.7 | -10.4 | 29.9 | −44.9% |
| 2023 | 15.1 | -4.3 | -32.3 | 104.1 | -0.9 | -6.7 | -2.4 | -11.1 | -12.5 | 58.7 | -2.8 | -29.2 | +16.6% |
| 2022 | -25.6 | -14.6 | -24.2 | -33.5 | -21.6 | -26.0 | -25.5 | -35.2 | 0.1 | 28.4 | 20.0 | -45.4 | −92.4% |
| 2021 | -2.6 | 1.3 | -0.3 | 0.4 | -0.5 | 0.6 | 1.1 | -21.5 | 37.7 | -28.3 | −22.5% |
Buy / hold / sell counts
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.